|
PT1071700E
(pt)
|
1998-04-20 |
2010-04-23 |
Glycart Biotechnology Ag |
Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
|
|
CA2838062C
(en)
|
2001-08-03 |
2015-12-22 |
Roche Glycart Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
WO2006082515A2
(en)
*
|
2005-02-07 |
2006-08-10 |
Glycart Biotechnology Ag |
Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
|
|
AR062223A1
(es)
*
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
|
MX2009012838A
(es)
|
2007-06-06 |
2009-12-11 |
Hoffmann La Roche |
Composicion de un primer anticuerpo monoclonal no marcado que se aglutina a un antigeno tumoral y a un segundo anticuerpo monoclonal de reaccion no cruzada marcado con un marcador fluorescsente del infrarrojo proximo.
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
MX2011003133A
(es)
*
|
2008-09-26 |
2011-04-21 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-egfr/anti-igf-1r.
|
|
CA2754646A1
(en)
*
|
2009-03-31 |
2010-10-07 |
Roche Glycart Ag |
Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan
|
|
US20100247484A1
(en)
|
2009-03-31 |
2010-09-30 |
Heinrich Barchet |
Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
|
|
WO2010112194A1
(en)
|
2009-04-02 |
2010-10-07 |
F. Hoffmann-La Roche Ag |
Antigen-binding polypeptides and multispecific antibodies comprising them
|
|
CN102369215B
(zh)
|
2009-04-02 |
2015-01-21 |
罗切格利卡特公司 |
包含全长抗体和单链Fab片段的多特异性抗体
|
|
SG175078A1
(en)
*
|
2009-04-07 |
2011-11-28 |
Roche Glycart Ag |
Bispecific anti-erbb-1/anti-c-met antibodies
|
|
SI2417156T1
(sl)
|
2009-04-07 |
2015-06-30 |
Roche Glycart Ag |
Trivalentna, bispecifiäśna protitelesa
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
MX2012003396A
(es)
|
2009-09-16 |
2012-04-10 |
Genentech Inc |
Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos.
|
|
CA2783715A1
(en)
*
|
2009-12-29 |
2011-07-07 |
F. Hoffmann-La Roche Ag |
Novel antibody formulation
|
|
IN2012DN06309A
(OSRAM)
*
|
2010-01-11 |
2015-09-25 |
Alexion Pharma Inc |
|
|
US20110200595A1
(en)
*
|
2010-02-18 |
2011-08-18 |
Roche Glycart |
TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
|
|
AR080793A1
(es)
*
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
|
CN101875697B
(zh)
*
|
2010-04-15 |
2014-04-30 |
北京天广实生物技术股份有限公司 |
新型抗egfr人源抗体tgm10的设计及其应用
|
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
CN102153647B
(zh)
*
|
2011-01-27 |
2012-07-04 |
中国人民解放军军事医学科学院生物工程研究所 |
一种抗egfr人源化抗体l3-h3及其编码基因与应用
|
|
JP2014511147A
(ja)
|
2011-02-10 |
2014-05-12 |
ロシュ グリクアート アーゲー |
改善された免疫療法
|
|
WO2012116926A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Antigen binding proteins
|
|
BR112013020338A2
(pt)
|
2011-02-28 |
2016-10-18 |
Hoffmann La Roche |
proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira
|
|
US9152861B2
(en)
*
|
2011-03-04 |
2015-10-06 |
Nec Corporation |
Individual product identification system, individual product identification method, and device and program used by same
|
|
KR101681818B1
(ko)
|
2011-08-23 |
2016-12-01 |
로슈 글리카트 아게 |
T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
|
|
US20130078250A1
(en)
|
2011-08-23 |
2013-03-28 |
Oliver Ast |
Bispecific t cell activating antigen binding molecules
|
|
RU2650775C2
(ru)
|
2011-08-23 |
2018-04-17 |
Рош Гликарт Аг |
Биспецифические антигенсвязывающие молекулы
|
|
NO2748201T3
(OSRAM)
|
2011-08-23 |
2018-05-12 |
|
|
|
EP2748197A2
(en)
|
2011-08-26 |
2014-07-02 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
|
CA2845147A1
(en)
|
2011-09-23 |
2013-03-28 |
Roche Glycart Ag |
Bispecific anti-egfr/anti igf-1r antibodies
|
|
WO2013113641A1
(en)
|
2012-01-31 |
2013-08-08 |
Roche Glycart Ag |
Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
|
|
CN104105711B
(zh)
|
2012-02-10 |
2018-11-30 |
弗·哈夫曼-拉罗切有限公司 |
单链抗体及其他异多聚体
|
|
MX2014010379A
(es)
|
2012-03-02 |
2015-05-15 |
Roche Glycart Ag |
Biomarcador predictivo para tratamiento de cancer con anticuerpos mejorados en adcc.
|
|
CN104394879A
(zh)
*
|
2012-03-27 |
2015-03-04 |
株式会社绿十字 |
表皮生长因子受体表面抗原的表位及其用途
|
|
JP6441792B2
(ja)
*
|
2012-05-17 |
2018-12-19 |
ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
Ｅｇｆｒに結合する抗原結合蛋白質
|
|
EP2867254B1
(en)
|
2012-06-27 |
2017-10-25 |
F. Hoffmann-La Roche AG |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
|
KR20150023889A
(ko)
|
2012-06-27 |
2015-03-05 |
에프. 호프만-라 로슈 아게 |
2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도
|
|
CA2872195A1
(en)
|
2012-08-07 |
2014-02-13 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
|
EP2904016B1
(en)
|
2012-10-08 |
2018-11-14 |
Roche Glycart AG |
Fc-free antibodies comprising two fab-fragments and methods of use
|
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
|
WO2014114595A1
(en)
|
2013-01-23 |
2014-07-31 |
Roche Glycart Ag |
Predictive biomarker for cancer treatment with adcc-enhanced antibodies
|
|
MX2015010843A
(es)
|
2013-02-26 |
2016-04-04 |
Roche Glycart Ag |
Moleculas biespecificas de union al antigeno que activan celulas t.
|
|
EP3444278A1
(en)
|
2013-02-26 |
2019-02-20 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
|
KR20180023035A
(ko)
|
2013-02-26 |
2018-03-06 |
로슈 글리카트 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
|
US9458245B2
(en)
|
2013-03-06 |
2016-10-04 |
Merrimack Pharmaceuticals, Inc. |
ANTI-C-MET tandem Fc bispecific antibodies
|
|
MX2015014773A
(es)
*
|
2013-04-22 |
2016-03-04 |
Glycotope Gmbh |
Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja.
|
|
KR20160044060A
(ko)
|
2013-10-11 |
2016-04-22 |
에프. 호프만-라 로슈 아게 |
다중특이적 도메인 교환된 통상의 가변 경쇄 항체
|
|
JP2016538283A
(ja)
|
2013-11-13 |
2016-12-08 |
ザイムワークス，インコーポレイテッド |
Ｅｇｆｒ及び／またはｈｅｒ２を標的にする一価抗原結合性構築物及びその使用
|
|
BR112016020009A2
(pt)
*
|
2014-04-10 |
2017-10-17 |
Obi Pharma Inc |
anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma
|
|
DK3177643T3
(da)
|
2014-08-04 |
2019-07-15 |
Hoffmann La Roche |
Bispecifikke T-celle-aktiverende antigenbindende molekyler
|
|
US9616114B1
(en)
|
2014-09-18 |
2017-04-11 |
David Gordon Bermudes |
Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
|
|
EP3659625A1
(en)
|
2014-10-23 |
2020-06-03 |
Innate Pharma |
Treatment of cancers using anti-nkg2a agents
|
|
DK4141032T3
(da)
|
2014-11-20 |
2024-08-05 |
Hoffmann La Roche |
Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler og PD-1-aksebindende antagonister
|
|
DK3221356T3
(da)
|
2014-11-20 |
2020-11-02 |
Hoffmann La Roche |
T-celleaktiverende, bispecifikke, antigenbindende molekyler mod folr1 og cd3
|
|
DK3221357T3
(da)
|
2014-11-20 |
2020-08-10 |
Hoffmann La Roche |
Fælles letkæder og fremgangsmåder til anvendelse
|
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
|
CN107949574A
(zh)
|
2015-10-02 |
2018-04-20 |
豪夫迈·罗氏有限公司 |
双特异性t细胞活化性抗原结合分子
|
|
WO2017055391A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific t cell activating antigen binding molecules binding mesothelin and cd3
|
|
WO2017055395A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
|
WO2017055314A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
KR20180073561A
(ko)
|
2015-10-02 |
2018-07-02 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
|
|
KR102850929B1
(ko)
|
2015-12-09 |
2025-08-27 |
에프. 호프만-라 로슈 아게 |
항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체
|
|
ES2837428T3
(es)
|
2016-01-08 |
2021-06-30 |
Hoffmann La Roche |
Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3
|
|
PE20181891A1
(es)
|
2016-03-22 |
2018-12-11 |
Hoffmann La Roche |
Moleculas biespecificas de celulas t activadas por proteasas
|
|
JP7015244B2
(ja)
|
2016-03-22 |
2022-02-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化ｔ細胞二重特異性分子
|
|
US10753936B2
(en)
|
2016-07-22 |
2020-08-25 |
Van Andel Research Institute |
Method of detecting the level of a glycan
|
|
ES2897217T3
(es)
|
2016-09-30 |
2022-02-28 |
Hoffmann La Roche |
Anticuerpos biespecíficos frente a p95HER2
|
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
|
PE20200152A1
(es)
|
2017-03-27 |
2020-01-17 |
Hoffmann La Roche |
Receptores de union a antigeno mejorados
|
|
EP3600408A1
(en)
|
2017-03-27 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Improved antigen binding receptor formats
|
|
CN110382525B
(zh)
|
2017-04-03 |
2023-10-20 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
|
JP7426825B2
(ja)
|
2017-04-03 |
2024-02-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｐｄ－１抗体と突然変異ｉｌ－２とまたはｉｌ－１５とのイムノコンジュゲート
|
|
AU2018247767B2
(en)
|
2017-04-03 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to STEAP-1
|
|
TWI707871B
(zh)
|
2017-04-05 |
2020-10-21 |
瑞士商赫孚孟拉羅股份公司 |
抗lag3抗體
|
|
BR112019021411A2
(pt)
|
2017-04-13 |
2020-05-05 |
Hoffmann La Roche |
métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção
|
|
GB201710836D0
(en)
*
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
ROR1 Car T-Cells
|
|
CN107881160A
(zh)
*
|
2017-08-11 |
2018-04-06 |
百奥泰生物科技(广州)有限公司 |
一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法
|
|
WO2019126536A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals Inc. |
Humanized anti-cd200 antibodies and uses thereof
|
|
WO2019126133A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals, Inc. |
Liquid formulations of anti-cd200 antibodies
|
|
WO2019122052A2
(en)
|
2017-12-21 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a2/wt1
|
|
JP7394058B2
(ja)
|
2017-12-21 |
2023-12-07 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
新規抗原結合部分の特異性試験のためのユニバーサルレポーター細胞アッセイ
|
|
EP3731865A1
(en)
|
2017-12-29 |
2020-11-04 |
F. Hoffmann-La Roche AG |
Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
|
|
CN118772288A
(zh)
|
2018-02-08 |
2024-10-15 |
豪夫迈·罗氏有限公司 |
双特异性抗原结合分子和使用方法
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
JP2021519073A
(ja)
|
2018-03-29 |
2021-08-10 |
ジェネンテック， インコーポレイテッド |
哺乳動物細胞におけるラクトジェニック活性の制御
|
|
JP7609771B2
(ja)
*
|
2018-06-01 |
2025-01-07 |
エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント |
タンパク質と細胞のグリカン分析
|
|
PE20211603A1
(es)
|
2018-12-21 |
2021-08-18 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3
|
|
CN113286822A
(zh)
|
2018-12-21 |
2021-08-20 |
豪夫迈·罗氏有限公司 |
靶向肿瘤的超激动性cd28抗原结合分子
|
|
US11608376B2
(en)
|
2018-12-21 |
2023-03-21 |
Hoffmann-La Roche Inc. |
Tumor-targeted agonistic CD28 antigen binding molecules
|
|
CN119708247A
(zh)
|
2018-12-21 |
2025-03-28 |
豪夫迈·罗氏有限公司 |
与VEGF和IL-1β结合的抗体及其使用方法
|
|
US20220025045A1
(en)
|
2018-12-26 |
2022-01-27 |
Innate Pharma |
Compounds and methods for treatment of head and neck cancer
|
|
BR112021026293A2
(pt)
|
2019-06-26 |
2022-03-03 |
Hoffmann La Roche |
Moléculas de ligação, anticorpos humanizados, ácido nucleico isolado, célula hospedeira, métodos para produzir a molécula de ligação ao antígeno, para tratar um indivíduo e suprarregular ou prolongar a atividade de células t citotóxicas, composição farmacêutica e uso da molécula
|
|
JP2022538139A
(ja)
|
2019-07-02 |
2022-08-31 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
変異体インターロイキン－２及び抗ｃｄ８抗体を含む免疫複合体
|
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
CA3147420A1
(en)
|
2019-07-26 |
2021-02-04 |
Abl Bio Inc. |
Anti-egfr/anti-4-1bb bispecific antibody and use thereof
|
|
JP2022543551A
(ja)
|
2019-07-31 |
2022-10-13 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｇｐｒｃ５ｄに結合する抗体
|
|
PE20220394A1
(es)
|
2019-07-31 |
2022-03-18 |
Hoffmann La Roche |
Anticuerpos que se fijan a gprc5d
|
|
AU2020349509A1
(en)
|
2019-09-18 |
2022-03-31 |
Genentech, Inc. |
Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
|
|
MX2022007635A
(es)
|
2019-12-18 |
2022-07-19 |
Hoffmann La Roche |
Anticuerpos que se unen a hla-a2/mage-a4.
|
|
CN111018990A
(zh)
*
|
2020-02-10 |
2020-04-17 |
张喜田 |
一种新型的重组抗表皮生长因子受体单克隆抗体及其应用
|
|
CA3169908A1
(en)
|
2020-03-26 |
2021-09-30 |
Genentech, Inc. |
Modified mammalian cells having reduced host cell proteins
|
|
PE20230111A1
(es)
|
2020-04-15 |
2023-01-27 |
Hoffmann La Roche |
Inmunoconjugados
|
|
EP4149524A1
(en)
|
2020-05-11 |
2023-03-22 |
F. Hoffmann-La Roche AG |
Combination therapy with modified pbmcs and an immunoconjugate
|
|
BR112022024996A2
(pt)
|
2020-06-08 |
2022-12-27 |
Hoffmann La Roche |
Anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, agente terapêutico, uso do anticorpo e método para tratar um indivíduo com hepatite b
|
|
PE20230835A1
(es)
|
2020-06-19 |
2023-05-19 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3
|
|
BR112022025856A2
(pt)
|
2020-06-19 |
2023-01-10 |
Hoffmann La Roche |
Anticorpo que se liga a cd3 e cd19, polinucleotídeo isolado, célula hospedeira, método de produção de um anticorpo que se liga a cd3 e cd19, composição farmacêutica, uso do anticorpo, método para tratar uma doença em um indivíduo e invenção
|
|
IL296429A
(en)
|
2020-06-19 |
2022-11-01 |
Hoffmann La Roche |
Protease-activated t-cell bispecific antibodies
|
|
JP2023529981A
(ja)
|
2020-06-19 |
2023-07-12 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
免疫活性化Ｆｃドメイン結合分子
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
PE20230616A1
(es)
|
2020-06-19 |
2023-04-14 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y folr1
|
|
PE20231361A1
(es)
|
2020-06-23 |
2023-09-05 |
Hoffmann La Roche |
Moleculas agonistas de union al antigeno cd28 que se dirigen a her2
|
|
MX2022016453A
(es)
|
2020-06-24 |
2023-02-01 |
Genentech Inc |
Lineas celulares resistentes a la apoptosis.
|
|
EP4172203A1
(en)
|
2020-06-25 |
2023-05-03 |
F. Hoffmann-La Roche AG |
Anti-cd3/anti-cd28 bispecific antigen binding molecules
|
|
IL298921A
(en)
|
2020-07-10 |
2023-02-01 |
Hoffmann La Roche |
Antibodies which bind to cancer cells and target radionuclides to said cells
|
|
IL299799A
(en)
|
2020-07-17 |
2023-03-01 |
Genentech Inc |
Anti-NOTCH2 antibodies and methods of use
|
|
IL298449A
(en)
|
2020-08-03 |
2023-01-01 |
Hoffmann La Roche |
Enhanced receptors for antigen binding
|
|
JP2023539201A
(ja)
|
2020-08-28 |
2023-09-13 |
ジェネンテック， インコーポレイテッド |
宿主細胞タンパク質のＣＲＩＳＰＲ／Ｃａｓ９マルチプレックスノックアウト
|
|
JP7158626B1
(ja)
|
2020-09-04 |
2022-10-21 |
エフ．ホフマン－ラ ロシュ アーゲー |
Ｖｅｇｆ－ａ及びａｎｇ２に結合する抗体及び使用方法
|
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
|
WO2022090181A1
(en)
|
2020-10-28 |
2022-05-05 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptors
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
MX2023008084A
(es)
|
2021-01-12 |
2023-07-13 |
Hoffmann La Roche |
Anticuerpos split que se unen a celulas cancerosas y dirigen radionuclidos a dichas celulas.
|
|
WO2022152701A1
(en)
|
2021-01-13 |
2022-07-21 |
F. Hoffmann-La Roche Ag |
Combination therapy
|
|
WO2022169872A1
(en)
|
2021-02-03 |
2022-08-11 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
|
CN117062839A
(zh)
|
2021-03-12 |
2023-11-14 |
基因泰克公司 |
抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体和使用方法
|
|
US20240376171A1
(en)
|
2021-03-30 |
2024-11-14 |
Hoffmann-La Roche Inc. |
Protease-activated polypeptides
|
|
TW202305122A
(zh)
|
2021-04-19 |
2023-02-01 |
美商建南德克公司 |
經修飾之哺乳動物細胞
|
|
EP4330282A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
EP4341385A1
(en)
|
2021-05-21 |
2024-03-27 |
Genentech, Inc. |
Modified cells for the production of a recombinant product of interest
|
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
|
TW202306985A
(zh)
|
2021-07-12 |
2023-02-16 |
美商建南德克公司 |
降低抗體－脂酶結合之結構
|
|
CA3224853A1
(en)
|
2021-07-14 |
2023-01-19 |
Gautham GAMPA |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
|
AU2022315528A1
(en)
|
2021-07-22 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
|
WO2023062050A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
|
WO2023062048A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
|
PE20241586A1
(es)
|
2021-11-25 |
2024-08-01 |
Hoffmann La Roche |
Receptores de union al antigeno mejorados
|
|
JP2024543257A
(ja)
|
2021-11-26 |
2024-11-20 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｔｙｒｐ１／抗ｃｄ３二重特異性抗体およびｔｙｒｐ１特異性抗体の併用療法
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
CN116333117B
(zh)
*
|
2021-12-16 |
2024-04-26 |
徕特康(苏州)生物制药有限公司 |
抗表皮生长因子受体抗体及其制备方法和用途
|
|
CN116333116B
(zh)
*
|
2021-12-16 |
2024-03-05 |
徕特康(苏州)生物制药有限公司 |
抗表皮生长因子受体抗体及其制备方法和用途
|
|
TW202340251A
(zh)
|
2022-01-19 |
2023-10-16 |
美商建南德克公司 |
抗ｎｏｔｃｈ２抗體及結合物及其使用方法
|
|
WO2023151661A1
(zh)
|
2022-02-11 |
2023-08-17 |
江苏恒瑞医药股份有限公司 |
免疫缀合物及其用途
|
|
WO2023180511A1
(en)
|
2022-03-25 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Improved chimeric receptors
|
|
AR129268A1
(es)
|
2022-05-11 |
2024-08-07 |
Hoffmann La Roche |
Anticuerpo que se une a vegf-a e il6 y métodos de uso
|
|
AU2023320333A1
(en)
|
2022-08-01 |
2025-01-16 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
|
EP4594345A1
(en)
|
2022-09-29 |
2025-08-06 |
F. Hoffmann-La Roche AG |
Protease-activated polypeptides
|
|
US20240228620A1
(en)
|
2022-10-06 |
2024-07-11 |
Bicara Therapeutics Inc. |
Multispecific proteins and related methods
|
|
EP4598959A1
(en)
|
2022-10-07 |
2025-08-13 |
Genentech, Inc. |
Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
|
|
WO2024094741A1
(en)
|
2022-11-03 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Combination therapy with anti-cd19/anti-cd28 bispecific antibody
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
WO2024104933A1
(en)
|
2022-11-15 |
2024-05-23 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules
|
|
CN120077072A
(zh)
|
2022-11-29 |
2025-05-30 |
江苏恒瑞医药股份有限公司 |
Cldn18.2/4-1bb结合蛋白及其医药用途
|
|
CN119998314A
(zh)
|
2022-12-08 |
2025-05-13 |
长春百克生物科技股份公司 |
特异性结合rsv的抗体
|
|
AR131638A1
(es)
|
2023-01-18 |
2025-04-16 |
Genentech Inc |
Anticuerpos multiespecíficos y usos de estos
|
|
CN120676957A
(zh)
|
2023-01-20 |
2025-09-19 |
豪夫迈·罗氏有限公司 |
重组Fc结构域-IL2变体多肽以及与膜锚定抗原结合多肽的组合疗法
|
|
WO2024156672A1
(en)
|
2023-01-25 |
2024-08-02 |
F. Hoffmann-La Roche Ag |
Antibodies binding to csf1r and cd3
|
|
TW202438515A
(zh)
|
2023-02-06 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫調節組合物及相關方法
|
|
WO2024184287A1
(en)
|
2023-03-06 |
2024-09-12 |
F. Hoffmann-La Roche Ag |
Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
|
|
CN120858109A
(zh)
|
2023-03-10 |
2025-10-28 |
基因泰克公司 |
与蛋白酶的融合物及其用途
|
|
AU2024248331A1
(en)
|
2023-03-31 |
2025-10-09 |
Genentech, Inc. |
Anti-alpha v beta 8 integrin antibodies and methods of use
|
|
WO2024208777A1
(en)
|
2023-04-03 |
2024-10-10 |
F. Hoffmann-La Roche Ag |
All-in-one agonistic antibodies
|
|
CN120917044A
(zh)
|
2023-04-03 |
2025-11-07 |
豪夫迈·罗氏有限公司 |
激动性拆分型抗体
|
|
AR132623A1
(es)
|
2023-05-08 |
2025-07-16 |
Hoffmann La Roche |
PROTEÍNAS DE FUSIÓN DE INTERFERÓN a DIRIGIDAS Y MÉTODOS DE USO
|
|
AR132687A1
(es)
|
2023-05-16 |
2025-07-23 |
Hoffmann La Roche |
Inmunoconjugados de il-2 regulados por pd-1 y sus usos
|
|
AR132805A1
(es)
|
2023-06-01 |
2025-07-30 |
Hoffmann La Roche |
Moléculas de unión al antígeno inmunoestimuladoras que se unen específicamente a bcma
|
|
TW202504918A
(zh)
|
2023-06-01 |
2025-02-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向ｂｃｍａ及ｃｄ２８的雙特異性抗體
|
|
WO2024263761A1
(en)
|
2023-06-22 |
2024-12-26 |
Genentech, Inc. |
Antibodies and uses thereof
|
|
WO2025024334A1
(en)
|
2023-07-21 |
2025-01-30 |
Marrow Therapeutics, Inc. |
Hematopoietic cell targeting conjugates and related methods
|
|
WO2025021838A1
(en)
|
2023-07-26 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025040567A1
(en)
|
2023-08-18 |
2025-02-27 |
F. Hoffmann-La Roche Ag |
Protease activatable fc domain binding molecules
|
|
AR133909A1
(es)
|
2023-09-25 |
2025-11-12 |
Hoffmann La Roche |
ANTICUERPO QUE SE UNE A C3bBb
|
|
WO2025099120A1
(en)
|
2023-11-09 |
2025-05-15 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies with conditional activity
|
|
WO2025125118A1
(en)
|
2023-12-11 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Protease activatable fc domain binding molecules
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
WO2025132503A1
(en)
|
2023-12-20 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Antibodies binding to ceacam5
|
|
WO2025133290A1
(en)
|
2023-12-21 |
2025-06-26 |
Temper Bio |
Protein for immune regulation
|
|
WO2025133042A2
(en)
|
2023-12-22 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Activatable fusion proteins and methods of use
|
|
WO2025149633A1
(en)
|
2024-01-12 |
2025-07-17 |
Laigo Bio B.V. |
Bispecific antigen binding proteins
|
|
US20250375499A1
(en)
|
2024-01-26 |
2025-12-11 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025202147A1
(en)
|
2024-03-27 |
2025-10-02 |
F. Hoffmann-La Roche Ag |
Interleukin-7 immunoconjugates
|
|
WO2025215060A1
(en)
|
2024-04-11 |
2025-10-16 |
F. Hoffmann-La Roche Ag |
Antibodies that specifically bind modified oligonucleotides
|
|
US20250353881A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|